OFFICERS

President
Caryn Lerman, PhD
USC Norris Comprehensive Cancer Center

Vice President/President-elect
Robert A. Winn, MD
VCU Massey Cancer Center

Immediate Past President
Roy A. Jensen, MD
The University of Kansas Cancer Center

Treasurer
David M. Gosky, MA, MBA
The Ohio State University

Executive Director
Jennifer W. Pegher, MA
Association of American Cancer Institutes

Ruben A. Mesa, MD
Mays Cancer Center at UT Health San Antonio MD Anderson

Anil K. Rustgi, MD
Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center

Joann B. Sweasy, PhD
University of Arizona Cancer Center

Cornelia Ulrich, PhD, MS
Huntsman Cancer Institute
University of Utah

Robert H. Vonderheide, MD, DPhil
Abramson Cancer Center of the University of Pennsylvania

NEW BOARD MEMBERS

Steven D. Leach, MD
Dartmouth Cancer Center

Kunle Odunsi, MD, PhD
The University of Chicago Medicine Comprehensive Cancer Center

Sarah Thayer, MD, PhD
Feist-Weiller Cancer Center, LSU Health Shreveport

BOARD OF DIRECTORS

Carlos L. Arteaga, MD
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center

Marcia Cruz-Correa, MD, PhD
University of Puerto Rico
Comprehensive Cancer Center

S. Gail Eckhardt, MD, FASCO
Livestrong Cancer Institutes
The University of Texas at Austin
Dell Medical School

On the cover: AACI’s 2022 Board of Directors and attendees at AACI’s first Leadership Diversity and Development Initiative Workshop reflect a shared commitment to pursuing equity in cancer health and the oncology workforce.

Photo credits: Cover and pages 3-6, 16 (lower right), Randy Belice; Pages 2, 10 (except Cancer Research Ally awardees), 13, 20 (top and lower left), David Riffel.
In 2022, AACI hosted the inaugural Leadership Diversity and Development Initiative (LDDI) Workshop and its first-ever meeting designed for new cancer center directors, both part of the latest AACI presidential initiative. Thus, the theme of this year’s report: “Advancing Leadership.”

Attended by a diverse group of emerging cancer center leaders, the 1.5-day LDDI workshop featured sessions such as leading with authenticity, navigating the pathway to cancer center leadership, mentoring prospective leaders, becoming an influential communicator, and collaborating effectively with institutional leaders.

The LDDI workshop is one element of AACI’s current presidential initiative. With the LDDI Steering Committee, we published “Leadership Diversity and Development in the Nation’s Cancer Centers” in the Journal of the National Cancer Institute. The report examined diversity among cancer center leaders and identified best practices to ensure a diverse pipeline of emerging leaders who are poised to succeed.

For the first time since 2019, AACI members met in person for the 14th Annual AACI CRI Meeting in July and the 2022 AACI/CCAF Annual Meeting in October. The return of face-to-face gatherings for AACI members enhanced opportunities for networking, collaboration, and education.

Just prior to opening the annual meeting, we offered a day-long meeting for new cancer center directors.

Leaders from AACI member centers shared lessons learned on topics such as navigating new Cancer Center Support Grant guidelines to promote diversity, equity, and inclusion; best practices for fundraising; and negotiating with institutional leaders.

In the spirit of collaboration, AACI expressed its support of President Biden’s renewed Cancer Moonshot, which was formally relaunched in February. The key priorities of the Moonshot align with those of AACI members and include improved cancer screening, the mitigation of cancer disparities, and collaboration with the greater cancer research community.

AACI endorsed the appointment of Dr. Monica Bertagnolli as the director of the National Cancer Institute (NCI). A surgical oncologist and longtime advocate of increasing diversity in cancer research, Dr. Bertagnolli is the first woman to fill the role. We look forward to continuing to work with the Biden administration and the NCI to advance our common goals and end cancer as we know it.

Also in 2022, the association welcomed Ellis Fischel Cancer Center, Houston Methodist Neal Cancer Center, Koch Institute for Integrative Cancer Research at MIT, and Northwell Health Cancer Institute, bringing its total number of cancer center members to 107.

We extend our appreciation to our members, as well as to our corporate and nonprofit partners, whose continued support helps advance our mission of accelerating progress against cancer.
MEETINGS

Dr. Caryn Lerman, AACI president

Dr. Douglas Lowy, principal deputy director, National Cancer Institute

Dr. Matthew Naylor, president and CEO, National WWI Museum and Memorial
Beginning in 1959, AACI’s early decades were marked by relatively informal gatherings of small groups of cancer institute directors.

Today, AACI boasts two large events—the AACI/CCAF Annual Meeting and the Annual AACI Clinical Research Innovation Meeting—and two new meetings, both launched in 2022, designed respectively to develop leadership and diversity at AACI member institutions and to support new cancer center directors.

Both the long-standing and newly minted meetings deliver on some of AACI’s core member services: providing networking opportunities; fostering partnerships between and among cancer centers; and promoting equity in cancer health and leadership.

2022 AACI/CCAF Annual Meeting

The 2022 AACI/CCAF Annual Meeting convened hundreds of AACI cancer center colleagues with leaders of national cancer research and advocacy groups, industry, and government health agencies. The meeting is unique in providing leaders from academic cancer centers with a forum to discuss important issues and develop best practices with their peers.

The 2022 annual meeting featured sessions on patient engagement in clinical trials; the evolution of the Cancer Moonshot; drug discovery and development; precision oncology; emerging from COVID-19; changes to the National Cancer Institute (NCI) Cancer Center Support Grant (CCSG); and an overview of AACI’s basic science centers.

New Directors Meeting

The day before the start of the AACI/CCAF annual meeting, AACI hosted a day of sessions for new cancer center directors — those who started their tenures in 2019 or later.

The meeting program offered candid guidance from established directors and other cancer center experts on challenges like communicating with institutional leaders, elevating the impact of the clinical trials office, and navigating community outreach and engagement.

14th Annual Clinical Research Innovation (CRI) Meeting

AACI’s Clinical Research Innovation (CRI) provides a network for cancer center clinical research leaders to share best practices around clinical trials office operations.

CRI’s 2022 annual meeting drew 444 in-person attendees, with an additional 117 joining virtually. They included clinical research office leaders, medical directors, cancer center administrators, patient advocates, and representatives from government and industry.

Several meeting sessions focused on diversity, equity, and inclusion. Other panel discussion topics included barriers to clinical trial participation; technology; clinical trial feasibility; and preparing for the NCI’s CCSG.


**Leadership Diversity and Development Initiative (LDDI) Workshop**

AACI hosted its first Leadership Diversity and Development Initiative (LDDI) Workshop in November in Chicago. Dr. Caryn Lerman, AACI president and director of the USC Norris Comprehensive Cancer Center, welcomed nearly 100 participants from 78 AACI cancer centers. The attendees represented a diverse group of cancer center leaders, as well as emerging leaders nominated by their centers. LDDI is Dr. Lerman’s AACI presidential initiative.

The meeting included a discussion led by Dr. Lerman and a distinguished group of panelists: Dr. Jay Hess, dean of the Indiana University School of Medicine; Thomas Jackiewicz, president of the University of Chicago Medical Center; and Dr. Jehni Robinson, chair of the Department of Medicine and associate dean for primary care at Keck School of Medicine, University of Southern California. They explored ways that cancer centers within academic medical centers can successfully align with department chairs, deans, and health system CEOs.

The LDDI meeting featured two three-hour workshops led by executive coaches. David Chow focused on “leading with authenticity and impact,” with Ephraim Schachter conducting a session about how to be a more influential communicator, from negotiating like a CEO to handling difficult conversations with colleagues.

AACI’s vice president/president-elect, Dr. Robert Winn, director of the VCU Massey Cancer Center, teamed with consultant Marcy Waldinger to talk about identifying and mentoring emerging cancer center leaders.

Facing page, top: A panel of past and present AACI cancer center directors offered insights and personal anecdotes on navigating the pathway to cancer center leadership. One piece of advice: delegation and teamwork are key—you don’t have to do it all as a cancer center director. Pictured L-R: Drs. George Weiner, Cornelia Ulrich, Kunle Odunsi, Michelle Le Beau, Chanita Hughes Halbert. Bottom photo: LDDI workshop attendees.
INITIATIVES AND PROGRAMS

Drs. Jasziianne Tolbert (left) and Eneida Nemecek
Many AACI member services are managed through four initiatives and a variety of related programs, including task forces, committees, subcommittees, and forums. These activities offer numerous opportunities for AACI cancer center faculty and staff to engage with each other and AACI.

**Clinical Research Innovation (CRI)**

CRI’s mission is to collect, evaluate, and share best practices that promote the efficient and effective operation of cancer clinical research offices, and to interact with key stakeholders to inform policy decisions and advocate for improvement in the national clinical trials enterprise.

Among its policy activities in 2022, the CRI Steering Committee and AACI’s Board of Directors developed recommendations related to clinical research infrastructure at community research sites; financial toxicity for patients; education among patients and physicians; enrollment criteria for clinical trials; and funding for clinical research. The recommendations were shared with the U.S. Department of Health and Human Services to support the Biden administration’s efforts to increase clinical trial diversity.

CTO Staff Retention Task Force recommendations were shared in an AACI Commentary. Dr. Leonidas C. Platanias, director, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, chaired the task force.

CRI oversees the following portfolio of programs aimed at improving cancer center clinical trial operations:

### CRI Education and Operations Subcommittee

The CRI Education and Operations Subcommittee provides a platform to discuss clinical trial office challenges in the wake of the COVID-19 pandemic and to develop standards for new and existing staff training programs.

### Clinical Trials Office (CTO) Medical Directors Forum

CTO Medical Directors Forum co-chairs Drs. Theresa L. Werner, Tara Lin, Stefan Grant, Thomas George, and Patricia LoRusso have established a CTO medical directors-only listserv to provide peer-to-peer networking, mentoring, and knowledge-sharing opportunities.

### Clinical Trials Office (CTO) Staff Retention Task Force

In 2022, the task force met with industry representatives and the National Cancer Institute, and convened monthly to survey AACI members and develop recommendations about the turnover in CTOs.

### Shared Investigator Platform (SIP) Task Force

In 2022, the task force helped AACI cancer centers implement the Shared Investigator Platform by hosting mini-webinars, meeting with SIP developer Cognizant, and helping to guide SIP enhancements to reduce duplicative work.
**INITIATIVES AND PROGRAMS**

**CAR T Initiative**
The AACI CAR T Initiative convenes cancer center clinicians and administrators to discuss challenges and offer solutions and best practices for managing and developing a CAR T therapy program. Collaboration is facilitated by topic-specific working groups, webinars, listserv discussions, monthly update calls, and in-person meetings. CAR T Initiative participants include staff and faculty at AACI member institutions.

**Physician Clinical Leadership Initiative (PCLI)**
PCLI is a resource for creating best practices as well as for comparing approaches to common problems facing clinical physician leaders, e.g., deputy directors, chief medical officers, physician-in-chief, or other similar titled positions. PCLI’s 10th annual meeting, held during the AACI/CCAF Annual Meeting, featured a panel discussion on “The Future of the Oncology Workforce with the Great Talent Swap”.

**Leadership Diversity and Development Initiative (LDDI)**
AACI’s latest presidential initiative focuses on leadership development with an emphasis on diversity. Dr. Caryn Lerman, AACI president and director of the USC Norris Comprehensive Cancer Center, chairs the LDDI Steering Committee.

**Member Survey**
An AACI survey examined diversity among cancer center leaders and identified best practices to ensure a diverse pipeline of emerging leaders. Dr. Lerman, along with a national group of AACI cancer center leaders, shared the survey results and recommendations in their paper “Leadership Diversity and Development in the Nation's Cancer Centers,” published in the *Journal of the National Cancer Institute*.

To build a diverse pipeline and develop emerging cancer center leaders, the report outlined best practices for recruiting, onboarding, and leadership development. These practices will be compiled in a cancer center leadership development kit and disseminated broadly.

**Member Survey**
PCLI gathered data on oncology providers’ perceptions of the Immediate Release of Clinical Information provision of the 21st Century Cures Act. A report on the survey results has been accepted for publication in 2023 by *JCO Oncology Practice*.
A diverse cancer center leadership workforce that is adequately prepared to address the increasing complexity in the nation’s cancer centers will maximize the organization’s potential and our ability to promote cancer health equity at a local and national level.

— AACI President Dr. Caryn Lerman
Awards

Left to right: Doug Ulman, Dr. Raphael E. Pollock, Dr. Electra Paskett

Senator Roy Blunt

Representative Donald M. Payne

Dr. Elizabeth Jaffee and AACI President Dr. Caryn Lerman
In 2022 AACI recognized outstanding achievement by colleagues and supporters in the cancer research community through the following awards.

**AACI Distinguished Scientist Award**

**Dr. Elizabeth Jaffee**

Dr. Elizabeth M. Jaffee is the deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. A world leader in understanding the complex interaction between the immune system and pancreatic cancer, she led the direct translational development of a first-generation granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting allogeneic vaccine platform that has served as a human model for studying anticancer immunity.

Dr. Jaffee has chaired the National Cancer Advisory Board, served as a co-chair of the Cancer Moonshot Blue Ribbon Panel, and works with the Biden administration as a member of the President’s Cancer Panel. As the 2022 AACI Distinguished Scientist awardee Dr. Jaffee delivered a keynote presentation on her research at the AACI/CCAF annual meeting.

Created in 2002, the award recognizes a major contributor to the field of cancer research. Recent awardees include Drs. William G. Kaelin, Jr., Douglas R. Lowy, Charles Perou, Carl June, James Allison, and Lewis Cantley.

**AACI Champion for Cures Award**

**Pelotonia**

In its first 13 years, Pelotonia—a three-day experience of cycling, entertainment, and volunteerism—has raised more than $236 million for The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. The dollars raised support projects that address many areas of cancer research, including prevention, diagnosis, treatment, psychosocial issues, accelerated drug development and large initiatives that help change the landscape of cancer care.

Dr. Raphael E Pollock, director of The Ohio State University Comprehensive Cancer Center, presented AACI’s Champion for Cures Award to Doug Ulman, Pelotonia’s chief executive officer, during the AACI/CCAF annual meeting.

The award was established in 2018 to recognize one or more people, who, through direct financial support of an AACI cancer center, demonstrate exceptional leadership in advancing cancer research and care and in inspiring others to do the same.

**AACI Cancer Health Equity Award**

**Dr. Electra Paskett**

Dr. Electra D. Paskett is the associate director for population sciences and community outreach and founding director of the Center for Cancer Health Equity at The Ohio State University Comprehensive Cancer Center. Dr. Paskett has led multidisciplinary teams of investigators in several large initiatives to understand and reduce disparities within the cancer center’s catchment area.

Dr. Paskett has served as past president of the American Society of Preventive Oncology and as a member of many committees of the American Society of Clinical Oncology, the American Cancer Society, and the American Association for Cancer Research. She is also a member of the Ohio Commission on Minority Health and the NCI’s National Cancer Advisory Board.

Created in 2021, the award honors an individual or group that demonstrates exceptional leadership in promoting health equity, mitigating cancer disparities, and advocating for diversity and inclusion at their cancer center.

**AACI Cancer Research Ally Award**

**Senator Roy Blunt**

**Representative Donald M. Payne, Jr.**

AACI’s Cancer Research Ally Award was presented in June during the 2022 AACI/AACR Hill Day to Senator Roy Blunt (R-MO) and Representative Donald M. Payne, Jr. (D-NJ).

During more than 25 years in Congress, Sen. Blunt demonstrated strong support for cancer research, patients with cancer, and improving the quality of cancer care. He retired in 2022.

Rep. Payne was the lead sponsor of the AACI-endorsed Removing Barriers to Colorectal Screening Act, which passed in late 2020, and has co-sponsored several other AACI-endorsed bills.
President Biden and AACI Executive Director Jennifer W. Pegher at the White House, February 2, 2022.
By leveraging the collective efforts of cancer centers across North America for maximum impact, AACI has unprecedented opportunities to exert influence on public policy related to cancer research.

AACI’s public issues work is guided in large part by the Government Relations (GR) Forum, which coordinates activity at AACI cancer centers to educate legislators about the cancer research community and its positive impact on patients. In addition, AACI hosts monthly Zoom meetings with cancer center GR colleagues and expert guests on federal issues impacting the cancer centers, while AACI’s Public Policy Resource Library tracks AACI-endorsed federal legislation.

**AACI in the Nation’s Capital**

**Cancer Moonshot and ARPA-H**
In February, AACI Executive Director Jennifer W. Pegher was at the White House for President Joe Biden’s announcement of the relaunch of the Cancer Moonshot, including plans to convene a “cancer cabinet” of government officials with the goal of cutting the cancer death rate in half by 2025. In July, the president announced Dr. Elizabeth Jaffee’s appointment to the President’s Cancer Panel. Dr. Jaffee, deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, received AACI’s 2022 Distinguished Scientist Award.

In September, Pegher attended an event at the John F. Kennedy Presidential Library and Museum in Boston, to hear President Biden share progress updates on the Cancer Moonshot.

On October 24, Pegher again visited the White House for the launch of the National Breast Cancer Roundtable and the National Roundtable on Cervical Cancer, led by the American Cancer Society, an AACI Sustaining Member. The following day, she visited Howard University for a discussion between U.S. Department of Health and Human Services Secretary Xavier Becerra, JD, and newly appointed ARPA-H Director Dr. Renee Wegrzyn.

AACI held its annual Government Relations (GR) Forum in October during the AACI/CCAF Annual Meeting in Kansas City. At the event, Matthew Swaback, from Sidney Kimmel Cancer Center at Jefferson Health, became the new AACI GR Steering Committee chair.
Hill Day

In June, AACI met with federal legislators during its 2022 virtual Hill Day, co-hosted with the American Association for Cancer Research. Cancer center directors, researchers, physician-scientists, cancer survivors, and other advocates made the case for robust, sustained federal investments in biomedical research—and cancer research in particular—through the National Institutes of Health (NIH) and the National Cancer Institute (NCI).

AACI also participated in numerous other advocacy events hosted by like-minded partners and AACI cancer centers, including ACT for NIH, the American Cancer Society Cancer Action Network, American Society for Clinical Oncology, the Coalition for Health Funding, Friends of Cancer Research, One Voice Against Cancer, Prevent Cancer Foundation, United for Medical Research, Moffitt Cancer Center, and Roswell Park Comprehensive Cancer Center.

Dr. Katherine Tossas, VCU Massey Cancer Center, and Elise Daniel, an ovarian cancer survivor, were featured speakers at AACI’s 2022 Hill Day.
NATIONAL CANCER INSTITUTE: A NEW LEADER AND A FOCUS ON FUNDING

AACI applauded the appointment in August of Dr. Monica Bertagnolli as the director of the NCI. She is the first woman to serve in the role and was the first woman to hold the title of chief of surgical oncology at AACI member center Dana-Farber Cancer Institute. Dr. Bertagnolli briefed cancer center leaders during an AACI Board of Directors meeting in December.

Persistently low NCI paylines and grant success rates (see chart at right) were a major focus of AACI advocacy in 2022, with two AACI Commentaries tackling the issue. NCI is currently only able to fund about one in eight research applications that are determined to be “meritorious.”

While we appreciate the ongoing commitment of Congress to providing steady, predictable increases in funding for the NIH and NCI, we know the percentage of research grants funded by the NCI lags that of other NIH institutes. Any shortfall leaves promising science—even potential cures—unfunded and may even discourage a new generation of emerging scientists from pursuing cancer research.”

— AACI President Dr. Caryn Lerman, in remarks at AACI’s 2022 Hill Day

<table>
<thead>
<tr>
<th>National Cancer Institute</th>
<th>13.8%</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institute of Allergy and Infectious Diseases</td>
<td>17.5%</td>
</tr>
<tr>
<td>National Institute on Aging</td>
<td>24.2%</td>
</tr>
<tr>
<td>National Heart, Lung and Blood Institute</td>
<td>20.5%</td>
</tr>
<tr>
<td>National Institute of General Medical Sciences</td>
<td>33.4%</td>
</tr>
<tr>
<td>National Institute of Neurological Disorders and Stroke</td>
<td>20.2%</td>
</tr>
<tr>
<td>National Institute of Diabetes, Digestive, and Kidney Diseases</td>
<td>22.7%</td>
</tr>
<tr>
<td>National Institute on Mental Health</td>
<td>22.1%</td>
</tr>
</tbody>
</table>

NIH Totals: 19.1%

Source: National Institutes of Health, Office of Budget
SHARING BEST PRACTICES

Poster session at the 14th Annual AACI CRI Meeting
One of AACI’s primary member services is providing ways to share best practices with the goal of improving cancer center operations and patient care. Beyond meetings and various communications tools, AACI fosters education through listservs, webinars, and poster and abstract presentations.

**CRI Posters and Abstracts**

The 14th Annual AACI Clinical Research Innovation (CRI) Meeting featured 74 abstracts from 28 cancer centers. Abstract topics spanned several areas of clinical trial operations, including quality assurance, community outreach and engagement, and trial start-up and activation.

Three winning abstracts were presented individually during the meeting:

**FIRST PLACE:** Successful Methods of Addressing Clinical Research Staff Turnover  
N. Nahmias, J. Sanchez, A. Olier-Pino, A. Allred, K. Aviles, L. Corrales  
Sylvester Comprehensive Cancer Center  
University of Miami Health System  

**SECOND PLACE:** Starting Off on the Right Foot: Elevating the Voice of Community Stakeholders During the IIT Development Process  
E. Monari, S. Szurek, A. Ivey, T. George, A. Anderson, E. Shenkman, C. Evans, A. Lawson-Ross  
University of Florida Health Cancer Center  

**THIRD PLACE:** Clinical Research Coordinator Workload Estimation and Tracking  
M. Repede, D. Beighley, K. Putz, A. Fritsche, G. Nowakowski  
Mayo Clinic Comprehensive Cancer Center  

They were submitted by authors representing the following cancer centers:

- Cedars-Sinai Cancer
- Fred Hutchinson Cancer Center
- Hollings Cancer Center, Medical University of South Carolina
- Memorial Sloan Kettering Cancer Center
- Roswell Park Comprehensive Cancer Center
- The Tisch Cancer Institute at Mount Sinai
- UAMS Winthrop P. Rockefeller Cancer Institute
- UNC Lineberger Cancer Center, University of North Carolina at Chapel Hill

In 2021 AACI started a listserv for **community outreach and engagement (COE)** professionals at AACI cancer centers. The listserv provides a platform for members to ask questions or reach out to others about COE-related topics and currently has nearly 250 participants.

AACHI’s new **Catchment Area Research and Data Science (CARDS)** listserv aims to build a supportive and collaborative community for those involved in cancer center data collection, analysis, and utilization. CARDS is for individuals from community outreach, biostatistics, cancer informatics and anywhere else in our cancer centers where this work is happening.

The **CTO Medical Directors** listserv is used by 53 medical directors and provides a forum for clinical trials office leaders to discuss their role and workplace and to create mentoring opportunities. Serving a similar function, the **CTO Administrative Directors** listserv counts 57 members.

The **Physician Clinical Leadership Initiative (PCLI)** listserv facilitates the sharing of best practices for clinic service physician leaders.
WEBINARS

AACI’s Physician Clinical Leadership Initiative hosted two webinars in 2022:

Career Development: Making the Transition From Training to Clinician Investigator

The webinar provided a practical discussion of paths to developing a career in clinical investigation in cancer research. Panelists were Stephen Freedland, MD, Jun Gong, MD, Arsen Osipov, MD, and Karen Reckamp, MD, MS, from Cedars-Sinai Cancer.

A Transdisciplinary “Tweetorial” With Seasoned Colleagues

Presenters Julie Sosa, MD, MA, FACS, MAMSE, FSSO, UCSF Helen Diller Family Comprehensive Cancer Center; Tatiana Prowell, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; Fumiko Chino, MD, Memorial Sloan Kettering Cancer Center; and Syed Ahmad, MD, University of Cincinnati Medical Center, discussed how they use social media to advance their careers and enhance collaborations with other physicians.
The Association of American Cancer Institutes (AACI) represents 107 premier academic and freestanding cancer centers in the United States and Canada. AACI is accelerating progress against cancer by enhancing the impact of academic cancer centers and promoting cancer health equity.
SUPPORTERS
The 2022 AACI/CCAF Annual Meeting and the 14th Annual Clinical Research Innovation (CRI) Meeting provided opportunities for supporters to interact with AACI members and representatives from cancer research-related organizations.

Supporters and exhibitors promoted their products and services to hundreds of meeting attendees including cancer center directors, executive administrators, and leaders of clinics, laboratories, and specialized research facilities. The inaugural Leadership Diversity and Development Initiative (LDDI) workshop also provided sponsorship opportunities for companies and industry members.

AACI received support in 2022 for its events and programs from:

- AbbVie
- Advarra
- American Society of Clinical Oncology
- BEK Health
- Bristol Myers Squibb
- Caris Life Sciences
- Cedars-Sinai
- Complion
- Deep 6 AI
- ECG Management Consultants
- Essex Management
- Florence
- Gilead
- GlaxoSmithKline (GSK)
- High Enroll
- Huron
- Inspirata
- IntegraConnect
- Janssen
- Merck
- Mint Medical
- nCoup
- Novartis
- Patient Resource
- Pfizer
- Servier
- Slope
- Takeda Oncology
- TriNetX
- Triomics
- UHealth-Miami
- Varian Medical Systems
- Veeva Systems
- Verily Life Sciences
- WellSky
- WCG
- Yunu, Inc.

Exhibitors at the 14th Annual CRI Meeting

- Advarra
- BEK Health
- Cedars-Sinai
- Complion
- Deep 6 AI
- Florence
- High Enroll
- Huron
- Mint Medical
- nCoup
- Slope
- Veeva
- Verily Life Sciences
- WCG
- WellSky

AACI appreciates the valuable assistance these companies provide with fulfilling the association's mission of enhancing the impact of leading academic cancer centers.

AACI REVENUE SOURCES

<table>
<thead>
<tr>
<th>Source</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership Dues</td>
<td>36%</td>
</tr>
<tr>
<td>Meeting Registration</td>
<td>27%</td>
</tr>
<tr>
<td>Meeting Support</td>
<td>7%</td>
</tr>
<tr>
<td>Grants</td>
<td>8%</td>
</tr>
<tr>
<td>Other Support/Donations</td>
<td>3%</td>
</tr>
<tr>
<td>Exhibitors</td>
<td>6%</td>
</tr>
<tr>
<td>Corporate Roundtable</td>
<td>13%</td>
</tr>
</tbody>
</table>
The AACI Corporate Roundtable provides a forum for AACI cancer centers to address topics of mutual interest with industry colleagues. Through the Corporate Roundtable, cancer centers interact directly with industry decision makers. This interaction leads to support for both new and ongoing AACI programs and initiatives. Roundtable members met in July during the 14th Annual Clinical Research Innovation (CRI) Meeting and again in October at the 2022 AACI/CCAF Annual Meeting. Discussions focused on topics such as trial activation; centralized monitoring to reduce on-site monitoring visits; health disparities in cancer research; diversity, equity, and inclusion; and CTO staff retention.

Corporate Roundtable members also participated in task forces with CRI Steering Committee members. The Task Force on Diversity, Equity, and Inclusion looked at barriers for minority and diverse patient populations in clinical enrollment and community engagement, as well as barriers faced by health care providers in improving accessibility. The Clinical Trial Office (CTO) Staff Retention Task Force met to address staffing shortages, turnover, and retention in clinical research offices at cancer centers.

AACI extends its gratitude for the commitment and support of its 2022 Corporate Roundtable members shown at left.
Illustrating AACI’s efforts to promote perspectives from cancer center leaders, 2022 began with an editorial at TheHill.com, co-authored by AACI President Dr. Caryn Lerman and Vice President/President-elect Dr. Robert A. Winn. The February piece leveraged the recent 50th anniversary of the National Cancer Act to underscore the value of cancer research and call for Congress to support President Biden’s plan to “end cancer as we know it.”

Throughout the year, AACI continued to utilize social media platforms to amplify messages and news from its members, exceeding 4,500 Twitter followers and re-establishing a presence on LinkedIn, a key platform for AACI members. The association kept members well-informed through its monthly publications, the AACI Update newsletter and Commentary editorial series.

Seven issues were authored or co-authored by cancer center directors:

- **Our Best Defense Against Cancer: Robust Funding is Essential to Continued Research Progress**
  Dr. Roy A. Jensen, The University of Kansas Cancer Center

- **Driving Change in Lung Cancer: Cancer Centers Must Ensure That Lung Screening Reaches Those Who Can Benefit Most**
  Dr. Candace S. Johnson, Roswell Park Comprehensive Cancer Center

- **Enhancing the Diversity of the Cancer Leadership Pipeline**
  Dr. Caryn Lerman, USC Norris Comprehensive Cancer Center

- **Democratizing Artificial Intelligence: Bringing Automated Machine Learning Technologies to Basic, Translational, and Clinical Cancer Researchers**
  Drs. Dan Theodorescu and Jason H. Moore, Cedars-Sinai Cancer

- **CTO Staff Retention Task Force Recommendations: Retaining and Recruiting Top Talent Amid the Great Resignation**
  Dr. Leonidas C. Platanias, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

- **The 2022 AACI/CCAF Annual Meeting: Cancer Center Collaboration Meets Federal Cancer Policy**
  Dr. Cornelia Ulrich, Huntsman Cancer Institute

- **Low NCI Paylines and Grant Success Rates Compromise Research Potential**
  Drs. Roy A. Jensen, The University of Kansas Cancer Center; Steven K. Libutti, Rutgers Cancer Institute of New Jersey; Thomas J. Lynch, Jr., Fred Hutchinson Cancer Center; and Leonidas C. Platanias, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Recognizing the profound impact that social issues can have on cancer patients and their families, AACI strengthened its stance on the overlapping public health crises of gun violence, racism, and discrimination, and added cancer health equity to its mission statement. AACI also released a brief response to the Supreme Court reversal of the 1973 ruling on Roe v. Wade, urging state leaders to consider how the decision may affect access to quality cancer prevention, screening, and treatment services.

AACI’s public health statement appeared in a round-up of comments from oncology and health care groups in The Cancer Letter (TCL). Additional TCL coverage of AACI in 2022 included articles on cancer center catchment area coverage, AACI annual meeting awardees, and Dr. Lerman’s presidential initiative.
ACI welcomed four new members in 2022, bringing total membership to 107 cancer centers across North America.

Ellis Fischel Cancer Center

Directed by Gerhard Hildebrandt, MD, FACS, Ellis Fischel Cancer Center became Missouri’s state-designated cancer center in 2004 and is a member of University of Missouri Health Care in Columbia, MO. Opened in 1940 as an 85-bed hospital, Ellis Fischel was the first cancer center west of the Mississippi River and the second in the country. With more than 200 cancer-focused researchers across four Missouri campuses, the center has launched a plan to create a consortium partnership with AACI member, Siteman Cancer Center.

Houston Methodist Dr. Mary and Ron Neal Cancer Center

Serving eight counties in Southeast Texas, Houston Methodist Dr. Mary and Ron Neal Cancer Center is led by Jenny Chang, MD. In 2022, the center announced a $25 million philanthropic gift from Dr. Mary and Ron Neal; the funding will bolster efforts to create impactful research, training, and outreach for the communities that the center serves, including seven locations across greater Houston. To address cancer disparities, the center has launched grant-funded programs such as mobile mammography units.

Koch Institute for Integrative Cancer Research at MIT

Designated by the National Cancer Institute (NCI) as a basic cancer research center, the Koch Institute for Integrative Cancer Research at MIT is led by Matthew Vander Heiden, MD, PhD. Comprised of more than 50 laboratories and over 1,000 researchers, who partner extensively with academic, clinical, and industry partners, as well as faculty-founded startup companies, the institute focuses on five strategic areas: nanotechnology-based drugs, detection and monitoring, metastasis, precision medicine, and immunology and immunotherapy.

Northwell Health Cancer Institute

Directed by Richard Barakat, MD, Northwell Health Cancer Institute (NHCI) treats more than 16,600 new cancer patients each year. The Northwell Health system includes 21 hospitals, nine ambulatory oncology centers, and about 400 physicians caring for patients with cancer. The institute is located on Long Island, in Lake Success, NY. In 2015, Northwell Health entered an affiliation agreement with AACI member Cold Spring Harbor Laboratory Cancer Center, leading to the creation of NHCI in 2017.
WITH APPRECIATION

AACI thanks outgoing board members Carlos Arteaga, MD, director, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center; S. Gail Eckhardt, MD, FASCO, director, Livestrong Cancer Institutes, The University of Texas at Austin, Dell Medical School; and Anil K. Rustgi, MD, director, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center.

THREE CANCER CENTER DIRECTORS JOIN AACI BOARD

Steven D. Leach, MD; Kunle Odunsi, MD, PhD; and Sarah Thayer, MD, PhD, were elected to AACI’s Board of Directors in 2022.

Dr. Leach has been director of the Dartmouth Cancer Center since 2017. A surgical oncologist and pancreatic cancer researcher, he is professor of molecular and systems biology, surgery, and medicine at Dartmouth’s Geisel School of Medicine; holds the Preston T. and Virginia R. Kelsey Distinguished Chair in Cancer; and serves as associate dean for cancer programs. Dr. Leach chaired AACI’s Annual Meeting Program Committee in 2020.

Dr. Odunsi is director of the University of Chicago Medicine Comprehensive Cancer Center and a gynecologic oncologist who specializes in the treatment of ovarian cancer. His research focuses on understanding the mechanisms of immune recognition and tolerance in ovarian cancer. Dr. Odunsi has served on AACI’s CAR T and Leadership Diversity and Development Initiative steering committees.

Dr. Thayer is an active surgeon-scientist and director of Feist-Weiller Cancer Center in Shreveport, Louisiana. She is a National Cancer Institute-funded investigator focused on breast and pancreatic cancers and holds the Carroll Feist Endowed Chair for the Study of Cancer at LSU Health Shreveport. Dr. Thayer also oversees the Partners in Wellness program, providing mobile outreach, education, and cancer screenings in rural north Louisiana.

NEW BOARD MEMBERS
2022 COMMITTEES

ANNUAL MEETING PROGRAM COMMITTEE
Chair: Cornelia Ulrich, MS, PhD
Huntsman Cancer Institute, University of Utah

Dario C. Altieri, MD
Ellen and Ronald Caplan Cancer Center of The Wistar Institute

Julie Brabbs, MBA
University of Michigan Rogel Cancer Center

David Darr, MSc, MBA
Duke Cancer Institute
Duke University Medical Center

Robert L. Ferris, MD, PhD
UPMC Hillman Cancer Center

Wendy Law, PhD
Fred Hutchinson Cancer Center

Caryn Lerman, PhD
USC Norris Comprehensive Cancer Center

Ruben A. Mesa, MD, FACP
Mays Cancer Center at UT Health San Antonio MD Anderson

Kunle Odunsi, MD, PhD
The University of Chicago Medicine Comprehensive Cancer Center

Jennifer W. Pogher, MA
Association of American Cancer Institutes

Jennifer Rogers, MBA
UMarky Cancer Center

CAR T STEERING COMMITTEE
Chair: Peter A. Riedell, MD
The University of Chicago Medicine Comprehensive Cancer Center

Lihua Elizabeth Budde, MD, PhD
City of Hope Comprehensive Cancer Center

Matthew H. Carabasi, MD
Sidney Kimmel Cancer Center at Jefferson Health

Clint L. Divine, MBA, MSM
The University of Kansas Cancer Center

Natalie Grover, MD
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Helen E. Heslop, MD, DSc
Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine

Frederick L. Locke, MD
Moffitt Cancer Center

Joseph McGuirk, DO, FACP
The University of Kansas Cancer Center

Kunle Odunsi, MD, PhD
The University of Chicago Medicine Comprehensive Cancer Center

Sheila Ouwerson, MPA
Holden Comprehensive Cancer Center, University of Iowa

Miguel-Angel Perales, MD
Memorial Sloan Kettering Cancer Center

David L. Porter, MD
Abramson Cancer Center of the University of Pennsylvania

Craig Sauter, MD
Cleveland Clinic Cancer Center

Joseph Uberti, MD, PhD
Karmann Cancer Institute
Wayne State University

CLINICAL RESEARCH INNOVATION (CRI) STEERING COMMITTEE
Chair: Tara L. Lin, MD
The University of Kansas Cancer Center

Leslie P. Byatt, CCRC, ACRP-PM
University of New Mexico Comprehensive Cancer Center

Tiffany Colvin, CCRC
University of Colorado Cancer Center

Thomas J. George, Jr., MD, FACP
University of Florida Health Cancer Center

Christopher Loertscher, MA
USC Norris Comprehensive Cancer Center

Patricia M. LoRusso, DO, PhD
Yale Cancer Center, Yale School of Medicine

Eneida Nemecek, MD, MS, MBA
OHIO Knight Cancer Institute

Bhanu Pappu, PhD, MHA
UT Southwestern Medical Center

Michael Sainz
Dartmouth Cancer Center

Anne Schnatterly, MBA, BSN, RN, CCRP
WVU Cancer Institute

Susanna Sellmann, MRT, BSc, CCRP
Princess Margaret Cancer Centre University Health Network

Rachna Shroff, MD, MS
The University of Arizona Cancer Center

Kate Shumate, MPA, CCRP
UCSF Helen Diller Family Comprehensive Cancer Center

CTO MEDICAL DIRECTORS COMMITTEE
Thomas J. George, Jr., MD, FACP
University of Florida Health Cancer Center

Stefan C. Grant, MD, JD, MBA
Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Tara L. Lin, MD
The University of Kansas Cancer Center

Theresa L. Werner, MD
Huntsman Cancer Institute
University of Utah

CTO MEDICAL DIRECTORS COMMITTEE

CRI EDUCATION AND OPERATIONS SUBCOMMITTEE
Elizabeth Anderson, MPH, BSN
Stanford Cancer Institute

Jonathan Aguilar
The University of Texas MD Anderson Cancer Center

Wendy Bloomer, PhD, CCRP
Duke Cancer Institute
Duke University Medical Center

Vanessa Cajaruauringa, CCRP
Cedars-Sinai Cancer

Erin Cebula
Wilmot Cancer Institute, UR Medicine

Doreen DeGray
Wilmot Cancer Institute, UR Medicine

Jilliann De Jong
The University of Kansas Cancer Center

Chloe Fournier
Duke Cancer Institute
Duke University Medical Center

Mary Horak, CCRP
UPMC Hillman Cancer Center

Christine Jerome, MS, CCRP
Sidney Kimmel Cancer Center at Jefferson Health

Fyalon Kerr, CCRP
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Rachel Kingsford, MS, CCRP
Huntsman Cancer Institute
University of Utah

Stacey Lewis, RN, BSN, OCN, BBA
Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Erin E. Lynch, MS, CCRP
Dartmouth Cancer Center

Holly Mccliean
Vanderbilt-Ingram Cancer Center

Nishita Parekh
Princess Margaret Cancer Centre University Health Network

Cary Passaglia, CCRP
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Yolanda Pitts
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center

Elizabeth Pon, CCRP
UCSF Helen Diller Family Comprehensive Cancer Center

Cynthia Sneddon, MPH, CCRC
University of Colorado Cancer Center

Jacqueline Stern, MEd
Vanderbilt-Ingram Cancer Center

Claire Sulkowski, CCRP
Dana-Farber Cancer Institute, Harvard Medical School

Schantel Williams
The Tisch Cancer Institute at Mount Sinai

CTO STAFF RETENTION TASK FORCE
Chair: Leonidas C. Platonias, MD, PhD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Philip Arlen, PhD
Sylvester Comprehensive Cancer Center
University of Miami Health System

Zeno Ashai, MBBS, MPH
USC Norris Comprehensive Cancer Center

Craig Bunnell, MD, MPH, MBA
Dana-Farber Cancer Institute, Harvard Medical School

Andrew Chapman, DO, FACP
Sidney Kimmel Cancer Center at Jefferson Health

David Gosky, MA, MBA
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Andrew Lassman, MD
Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center
<table>
<thead>
<tr>
<th>STATE</th>
<th>CENTER NAME</th>
<th>CITY, STATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALABAMA</td>
<td>O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham</td>
<td>Birmingham, Alabama</td>
</tr>
<tr>
<td>ARIZONA</td>
<td>Mayo Clinic Comprehensive Cancer Center, Arizona</td>
<td>Scottsdale, Arizona</td>
</tr>
<tr>
<td></td>
<td>The University of Arizona Cancer Center</td>
<td>Tucson, Arizona</td>
</tr>
<tr>
<td>ARKANSAS</td>
<td>UAMS Winthrop P. Rockefeller Cancer Institute</td>
<td>Little Rock, Arkansas</td>
</tr>
<tr>
<td>CALIFORNIA</td>
<td>Cedars-Sinai Cancer</td>
<td>Los Angeles, California</td>
</tr>
<tr>
<td></td>
<td>City of Hope Comprehensive Cancer Center</td>
<td>Duarte, California</td>
</tr>
<tr>
<td></td>
<td>Loma Linda University Cancer Center</td>
<td>Loma Linda, California</td>
</tr>
<tr>
<td></td>
<td>Salk Institute Cancer Center</td>
<td>La Jolla, California</td>
</tr>
<tr>
<td></td>
<td>Sanford Burnham Prebys Medical Discovery Institute</td>
<td>La Jolla, California</td>
</tr>
<tr>
<td></td>
<td>Stanford Cancer Institute</td>
<td>Palo Alto, California</td>
</tr>
<tr>
<td></td>
<td>UC Davis Comprehensive Cancer Center</td>
<td>Sacramento, California</td>
</tr>
<tr>
<td></td>
<td>UC San Diego Moores Cancer Center</td>
<td>La Jolla, California</td>
</tr>
<tr>
<td></td>
<td>UCI Chao Family Comprehensive Cancer Center</td>
<td>Orange, California</td>
</tr>
<tr>
<td></td>
<td>UCLA Jonsson Comprehensive Cancer Center</td>
<td>Los Angeles, California</td>
</tr>
<tr>
<td></td>
<td>UCSF Helen Diller Family Comprehensive Cancer Center</td>
<td>San Francisco, California</td>
</tr>
<tr>
<td></td>
<td>USC Norris Comprehensive Cancer Center</td>
<td>Los Angeles, California</td>
</tr>
<tr>
<td>COLORADO</td>
<td>University of Colorado Cancer Center</td>
<td>Aurora, Colorado</td>
</tr>
<tr>
<td>CONNECTICUT</td>
<td>Yale Cancer Center</td>
<td>New Haven, Connecticut</td>
</tr>
<tr>
<td>DISTRICT OF COLUMBIA</td>
<td>Georgetown Lombardi Comprehensive Cancer Center</td>
<td>Washington, District of Columbia</td>
</tr>
<tr>
<td>FLORIDA</td>
<td>Mayo Clinic Comprehensive Cancer Center, Florida</td>
<td>Jacksonville, Florida</td>
</tr>
<tr>
<td></td>
<td>Moffitt Cancer Center</td>
<td>Tampa, Florida</td>
</tr>
<tr>
<td></td>
<td>Sylvester Comprehensive Cancer Center University of Miami Health System</td>
<td>Miami, Florida</td>
</tr>
<tr>
<td></td>
<td>University of Florida Health Cancer Center</td>
<td>Gainesville, Florida</td>
</tr>
<tr>
<td>GEORGIA</td>
<td>Georgia Cancer Center, Augusta University</td>
<td>Augusta, Georgia</td>
</tr>
<tr>
<td></td>
<td>Winship Cancer Institute of Emory University</td>
<td>Atlanta, Georgia</td>
</tr>
<tr>
<td>HAWAI’I</td>
<td>University of Hawai’i Cancer Center</td>
<td>Honolulu, Hawai’i</td>
</tr>
<tr>
<td></td>
<td>University of Hawai’i at Mānoa</td>
<td>Mānoa, Hawai’i</td>
</tr>
<tr>
<td>ILLINOIS</td>
<td>Cancer Center at Illinois</td>
<td>Urbana, Illinois</td>
</tr>
<tr>
<td></td>
<td>Cardinal Bernardin Cancer Center Loyola University Medical Center</td>
<td>Maywood, Illinois</td>
</tr>
<tr>
<td></td>
<td>Robert H. Lurie Comprehensive Cancer Center</td>
<td>Chicago, Illinois</td>
</tr>
<tr>
<td></td>
<td>The University of Chicago Medicine Comprehensive Cancer Center</td>
<td>Chicago, Illinois</td>
</tr>
<tr>
<td></td>
<td>University of Illinois Cancer Center</td>
<td>Chicago, Illinois</td>
</tr>
<tr>
<td>INDIANA</td>
<td>Indiana University Melvin and Bren Simon Comprehensive Cancer Center</td>
<td>Indianapolis, Indiana</td>
</tr>
<tr>
<td></td>
<td>Purdue University Center for Cancer Research</td>
<td>West Lafayette, Indiana</td>
</tr>
<tr>
<td>IOWA</td>
<td>Holden Comprehensive Cancer Center University of Iowa</td>
<td>Iowa City, Iowa</td>
</tr>
<tr>
<td>KANSAS</td>
<td>The University of Kansas Cancer Center</td>
<td>Kansas City, Kansas</td>
</tr>
<tr>
<td>KENTUCKY</td>
<td>UK Markey Cancer Center</td>
<td>Lexington, Kentucky</td>
</tr>
<tr>
<td>LOUISIANA</td>
<td>Feist-Weiller Cancer Center LSU Health Shreveport</td>
<td>Shreveport, Louisiana</td>
</tr>
<tr>
<td></td>
<td>Louisiana Cancer Research Center</td>
<td>New Orleans, Louisiana</td>
</tr>
<tr>
<td></td>
<td>The Jackson Laboratory Cancer Center</td>
<td>Bar Harbor, Maine</td>
</tr>
<tr>
<td>MARYLAND</td>
<td>Murtha Cancer Center at Walter Reed Bethesda</td>
<td>Bethesda, Maryland</td>
</tr>
<tr>
<td></td>
<td>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University</td>
<td>Baltimore, Maryland</td>
</tr>
<tr>
<td>MASSACHUSETTS</td>
<td>Boston University Cancer Center</td>
<td>Boston, Massachusetts</td>
</tr>
<tr>
<td></td>
<td>Dana-Farber Cancer Institute Harvard Medical School</td>
<td>Boston, Massachusetts</td>
</tr>
<tr>
<td></td>
<td>Koch Institute for Integrative Cancer Research at MIT</td>
<td>Cambridge, Massachusetts</td>
</tr>
<tr>
<td>MICHIGAN</td>
<td>Karmanos Cancer Institute Wayne State University</td>
<td>Detroit, Michigan</td>
</tr>
<tr>
<td></td>
<td>University of Michigan Rogel Cancer Center</td>
<td>Ann Arbor, Michigan</td>
</tr>
<tr>
<td>MINNESOTA</td>
<td>Masonic Cancer Center University of Minnesota</td>
<td>Minneapolis, Minnesota</td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic Comprehensive Cancer Center University of Minnesota</td>
<td>Rochester, Minnesota</td>
</tr>
<tr>
<td>MISSISSIPPI</td>
<td>UMMC Cancer Center and Research Institute</td>
<td>Jackson, Mississippi</td>
</tr>
<tr>
<td>MISSOURI</td>
<td>Ellis Fischel Cancer Center Columbia, MO</td>
<td>Columbia, Missouri</td>
</tr>
<tr>
<td>SITEMAN CANCER CENTER</td>
<td>Siteman Cancer Center</td>
<td>St. Louis, Missouri</td>
</tr>
<tr>
<td>NEBRASKA</td>
<td>Fred &amp; Pamela Buffett Cancer Center</td>
<td>Omaha, Nebraska</td>
</tr>
</tbody>
</table>
NEW HAMPSHIRE
Dartmouth Cancer Center
Lebanon, New Hampshire

NEW JERSEY
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

NEW MEXICO
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico

NEW YORK
Cold Spring Harbor Laboratory Cancer Center
Cold Spring Harbor, New York
Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center
New York, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Montefiore Einstein Cancer Center
Bronx, New York
Northwell Health Cancer Institute
Lake Success, New York
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
New York, New York
Stony Brook Cancer Center
Stony Brook, New York
The Tisch Cancer Institute at Mount Sinai
New York, New York
Upstate Cancer Center
SUNY Upstate Medical University
Syracuse, New York
Wilmot Cancer Institute
UR Medicine
Rochester, New York

NORTH CAROLINA
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina

OHIO
Case Comprehensive Cancer Center
Cleveland, Ohio
Cleveland Clinic Cancer Center
Cleveland, Ohio
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Columbus, Ohio
University of Cincinnati Cancer Center
Cincinnati, Ohio

OKLAHOMA
Stephenson Cancer Center
University of Oklahoma
Oklahoma City, Oklahoma

OREGON
OHSU Knight Cancer Institute
Portland, Oregon

PENNsylvania
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania
Penn State Cancer Institute
Hershey, Pennsylvania
Sidney Kimmel Cancer Center at Jefferson Health
Philadelphia, Pennsylvania
Ellen and Ronald Caplan Cancer Center of the Wistar Institute
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

PUERTO RICO
University of Puerto Rico Comprehensive Cancer Center
San Juan, Puerto Rico

RHODE ISLAND
Legorreta Cancer Center at Brown University
Providence, Rhode Island

SOUTH CAROLINA
 Hollings Cancer Center
Medical University of South Carolina
Charleston, South Carolina

TENNESSEE
Comprehensive Cancer Center
St. Jude Children’s Research Hospital
Memphis, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

TEXAS
Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine
Houston, Texas
Houston Methodist
Dr. Mary and Ron Neal Cancer Center
Houston, Texas
Livestrong Cancer Institutes
The University of Texas at Austin Dell Medical School
Austin, Texas
Mays Cancer Center at UT Health San Antonio MD Anderson
San Antonio, Texas
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Texas Medical Branch Cancer Center
Galveston, Texas

UTAH
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah

VERMONT
The University of Vermont Cancer Center
Burlington, Vermont

VIRGINIA
University of Virginia Cancer Center
Charlottesville, Virginia
VCU Massey Cancer Center
Richmond, Virginia

WASHINGTON
Fred Hutchinson Cancer Center
Seattle, Washington

WEST VIRGINIA
WVU Cancer Institute
Morgantown, West Virginia

WISCONSIN
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

CANADA
BRITISH COLUMBIA
BC Cancer
Vancouver, British Columbia

ONTARIO
Princess Margaret Cancer Centre
University Health Network
Toronto, Ontario